Lingering biologic dilemmas about the status of the progenitor cells in myelodysplasia

Archives of Medical Research

Volumn 34, Issue 6, 2003, Pages 515-519

  Mundle, Suneel D ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Myelodysplasia syndromes; Progenitor cells; Proliferation

Indexed keywords

CD34 ANTIGEN;

APOPTOSIS; BONE MARROW; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TRANSFORMATION; DISEASE COURSE; DISEASE PREDISPOSITION; HUMAN; MODEL; MUTATION; MYELODYSPLASIA; REVIEW; STEM CELL;

EID: 0347635465     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2003.09.001     Document Type: Article

References (38)

1. Raza A. Evolving concepts in myelodysplastic syndromes. Mundle S., Raza A. Myelodysplastic syndromes & secondary acute myelogenous leukemia - directions for the new millennium. 2001;1-24 Kluwar Academic Publishers, Boston, MA, USA.
2. Olney H.J., Le Beau M.M. The cytogenetics and molecular biology of myelodysplastic syndromes. Bennett J.M. The myelodysplastic syndromes: pathobiology and clinical management. 2002;89-120 Marcel Dekker, Inc, New York.
3. Mayani H. In vitro biology of the hematopoietic system in myelodysplastic syndromes. Mundle S., Raza A. Myelodysplastic syndromes & secondary acute myelogenous leukemia - directions for the new millennium. 2001;25-43 Kluwar Academic Publishers, Boston, MA, USA.
4. White N.J., Nacheva E., Asimakopoulos F.A., Bloxham D., Paul B., Green A.R. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid and B cells. Blood. 83:1994;2809-2816.
5. Miura I., Kobayashi Y., Takahashi N., Saitoh K., Miura A.B. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence activated cell sorting. Br J Haematol. 110:2000;876-879.
6. Nilsson L., Astrand-Grudstrom I., Arvidsson I., Jacobsson B., Hellstrom-Lindberg R., Hast R., Jacobsen S.E. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood. 96:2000;2012-2021.
7. Saitoh K., Miura I., Takahashi N., Miura A.B. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Blood. 92:1998;2886-2892.
8. Nilsson L., Astrand-Grudstrom I., Anderson K., Arvidsson I., Hokland P., Bryder D., Kjeldsen L., Johansson B., Hellstrom-Lindberg R., Hast R., Jacobsen S.E. Involvement and functional impairment of the CD34+CD38-Thy1+ hematopoeitic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 100:2002;259-267.
9. Delforge M., Demuynck H., Verhoef G., Vandenberghe P., Zachee P., Maertens J., Van Duppen V., Boogaerts M.A. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematologic remission. Br J Haematol. 102:1998;486-494.
10. Mundle S., Venugopal P., Shetty V., Ali A., Chopra H., Rose S., Mativi B.Y., Gregory S., Preisler H., Raza A. The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol. 69:1999;152-159.
11. Parker J.E., Fishlock K.L., Czepulkowski B., Mijovic A., Pagliuca A., Mufti G.J. 'Low risk' myelodysplastic syndrome (MDS) is associated with excessive apoptosis and increased ratio of pro-versus anti-apoptosis bcl-2 related proteins. Br J Haematol. 103:1998;1075-1082.
12. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., Pagliuca A. The role of apoptosis, proliferation, and the bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 96:2000;3932-3938.
13. Rajapaksa R., Ginzton N., Rott L.S., Greenberg P.L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood. 88:1996;4275-4287.
14. 2+-dependent endonuclease in marrow CD34 positive and erythroid cells in myelodysplasia. Leuk Res. 21:1997;731-734.
15. Hoffman R., Fitting P., Preisler H., Raza A., Chyna B., Horrigan S., Westbrook C. Analysis of primitive hematopoietic progenitor cells in myelodysplastic syndromes. Blood. 92:(Suppl 1):1998;417a. (abstract #1724).
16. - cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation. Leukemia. 12:1998;882-886.
17. Martínez-Jaramillo G., Flores-Figueroa E., Sánchez-Valle E., Gutiérrez-Espíndola G., Gómez-Morales E., Montesinos J.J., Flores-Guzmán P., Chávez-González A., Alvarado-Moreno J.A., Mayani H. Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia. Leuk Res. 26:2002;955-963.
18. Lepelley P., Campergue L., Grardel N., Preudhomme C., Cosson A., Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol. 95:1996;368-371.
19. Shetty V., Hussaini S., Broady-Robinson L., Allampallam K., Mundle S., Borok R., Cartlidge J., Broderick E., Mazzoran L., Zorat F., Raza A. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high density fraction of bone marrow aspirates. Blood. 96:2000;1388-1392.
20. Span L.F.R., Dar S.E., Shetty V.T., Mundle S.D., Broady-Robinson L., Alvi S., Raymakers R.A.P., deWitte T., Raza A. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia. Leukemia. 12:1998;1685-1695.
21. Raza A., Mundle S., Iftikhar A., Gregory S., Marcus B., Khan Z., Alvi S., Shetty V., Dameron S., Wright V., Adler S., Loew J., Shott S., Ali N., Preisler H.D. Simultaneous assessment of cell kinetics and programmed cells death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol. 48:1995;143-154.
22. Raza A., Gezer S., Mundle S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Loew J., Alvi S., Chaney C., Showel J., Gregory S., Preisler H.D. Apoptosis in bone marrow biopsies involving stromal and hematopoietic cells in 45 patients with myelodysplastic syndromes. Blood. 86:1995;268-276.
23. Horikawa K., Nakakuma H., Kawaguchi T., Iwamoto N., Nagakura S., Kagimoto T., Taktsuki K. Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood. 90:1997;2716-2722.
24. Shetty V.T., Mundle S.D., Raza A. Pseudo Pelger-Huet anomaly in myelodysplastic syndrome: hyposegmented or apoptotic neutrophil? Blood. 98:2001;1273-1274.
25. Bouscary D., de Vos J., Guesnu M., Jondeau K., Viguier F., Melle J., Picard F., Dreyfus F., Fontenay-Roupie M. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 11:1997;839-845.
26. Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Ferrand A., Troutt A.E., Ledbetter J.A., Deeg H.J. A role for tumor necrosis factor-α, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 103:1998;176-188.
27. Gupta P., Niehans G.A., LeRoy S.C., Gupta K., Morrison V.A., Schultz C., Knapp D.J., Kratzke R.A. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia. 13:1999;44-53.
28. Deeg H.J., Beckham C., Loken M.R., Bryant E., Lesnikova M., Shulman H.M., Gooley T. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndromes. Leuk Lymphoma. 37:2000;405-414.
29. Dai C.-H., Price J.O., Brunner T., Krantz S.B. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by Interferon γ to produce erythroid cell apoptosis. Blood. 91:1998;1235-1242.
30. Fontenay-Roupie M., Bouscary D., Guesnu M., Picard F., Melle J., Lacombe C., Gisselbrecht S., Mayeux M., Dreyfus F. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol. 106:1999;464-473.
31. Mundle S., Mativi B.Y., Bagai K., Feldman G., Cheema P., Gautam U., Reza S., Cartlidge J., Venugopal P., Shetty V., Gregory S.A., Robin E., Rifkin S., Shah R., Raza A. Spontaneous down-regulation of Fas-associated phosphatase-1 (Fap-1) may contribute to the excessive apoptosis in myelodysplastic marrows. Int J Hematol. 70:1999;83-90.
32. Davis R.E., Greenberg P.L. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res. 22:1998;767-777.
33. Kurotaki H., Tsushima Y., Nagai K., Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol. 102:1999;115-123.
34. Padua R.A., McGlynn A., McGlynn H. Molecular, cytogenetic and genetic abnormalities in MDS and secondary AML. Mundle S., Raza A. Myelodysplastic syndromes & secondary acute myelogenous leukemia - directions for the new millennium. 2001;111-158 Kluwar Academic Publishers, Boston, MA, USA.
35. Raza A., Yousuf N., Bohkari S.A.J., Sheikh Y., Akhtar S., Chughtai S., Umerani A., Mehdi S.A., Miller M.A., Masterson M., Lampkin B. In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdU in patients with hematopoietic malignancies. Leuk Res. 16:1992;299-306.
36. Hamblin T.J. Immunology of the myelodysplastic syndromes. Bennett J.M. The myelodysplastic syndromes: pathobiology and clinical management. 2002;65-87 Marcel Dekker, New York.
37. Ali A., Mundle S.D., Ragasa D., Reza S., Shetty V., Mativi B.Y., Cartlidge J.D., Azharuddin M., Qawi H., Dar S., Raza A. Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res. 8:1999;343-356.
38. Pecci A., Travaglino E., Klersy C., Invernizzi R. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow. Acta Haematol. 109:2003;29-34.